HALIFAX, Nova Scotia, May 30, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (TSX:IMV) (OTCQX:IMMVD), a clinical stage
immuno-oncology company, today announced details on upcoming industry presentations that the company’s leadership will be making at
the 4th Annual Immuno-Oncology BD&L
and Investment (IOBDLI) Forum and the International Cancer Cluster Showcase (ICCS).
Chief Executive Officer Frederic
Ors will join in the IOBDLI Forum, which is taking place on June 1, 2018, at the Waldorf Astoria Hotel in Chicago. Mr. Ors will
present a corporate update, and participate in a panel discussion on recent industry innovations in targeted cancer
immunotherapies.
In addition, Joseph Sullivan,
IMV’s Senior Vice President of Business Development, will present an update on the Company’s progress and corporate strategy at
the ICCS on June 4, 2018, during the 2018 BIO International Convention, taking place at the Boston Convention Center.
Details for Mr. Ors’ IOBDLI events are as follows:
Plenary Session Panel Discussion
- Title: Cancer Vaccines and Neo Antigens Evaluating Latest Progress Panel
- Date: June 1, 2018
- Time: 11:20 a.m. – 12:00 p.m. CT
- Location: Waldorf Astoria Hotel
IMV Corporate Presentation:
- Date: June 1, 2018
- Time: 3:20 p.m. – 3:40 p.m. CT
- Presentation Track D
- Location: Waldorf Astoria Hotel, Sinclair Ballroom
Details for Mr. Sullivan’s ICCS presentation include:
- Date: June 4, 2018
- Time: 12:30 p.m. ET
- Location: Boston Convention Center, Level 2, Rooms 256 and 258A
About the Conferences
Immuno-Oncology BD&L and Investment (IOBDLI) Forum
Taking place on the first day of ASCO, the 4th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together
thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and
investment. Conference organizers expect approximately 200 delegates and over 20 presentations by listed and private biotechnology
companies seeking licensing and investment.
International Cancer Cluster Showcase (ICCS) 2018
The 7th International Cancer Cluster Showcase, taking place during the annual BIO International Convention in Boston, features 200+
representatives of the international oncology community. Participants from leading North American and European
biotech companies present innovations and latest R&D activities in compact four minute presentations.
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more
effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering
a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new
synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the
utility of the platform with a target: survivin. IMV is currently conducting three clinical studies with Incyte and Merck assessing
DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. Connect at www.imv-inc.com.
Contacts for IMV:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
